Form 4: Sutro Biopharma Director Acquires Stock Options

Heidi Hunter, a Director at Sutro Biopharma, Inc., acquired 10,000 stock options with an exercise price of $26.09.

Summary

• Heidi Hunter, a Director at Sutro Biopharma, Inc. (STRO), acquired 10,000 stock options on June 5, 2026.
• The options have an exercise price of $26.09 per share.
• These options are exercisable and will vest over time, with the first tranche vesting on July 5, 2026.
• The award is fully vested and exercisable by the earlier of the issuer's 2027 annual stockholders meeting or June 5, 2027.
• The reporting person is Heidi Hunter, and the filing is made by one reporting person.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard grant of stock options to a director, which is a common compensation practice and does not inherently signal a significant positive or negative development.

Positives

• Director acquisition of stock options can signal confidence in the company's future prospects.
• The options are granted with a specific exercise price, indicating a defined potential future value.
• The vesting schedule provides a retention incentive for the director.

Negatives

• The filing only reports the acquisition of options, not the exercise or sale of shares, so no immediate financial gain is reported.
• The exercise price of $26.09 is a benchmark that the stock price must exceed for the options to be profitable.

Risks

• The value of the stock options is contingent on the future performance of Sutro Biopharma's stock price.
• Market volatility and company-specific challenges could prevent the stock price from exceeding the exercise price.

Future Outlook

The stock options are subject to a vesting schedule, with full exercisability expected by June 5, 2027, or the date of the issuer's 2027 annual stockholders meeting, whichever comes first. The value realized from these options depends on the company's stock performance.

Industry Context

StockSavvy.ai notes that the acquisition of stock options by a director is a common practice in the biopharmaceutical industry, often used as a long-term incentive to align management's interests with those of shareholders. The specific exercise price and vesting schedule are typical for such equity awards.

Stakeholder Impact

• Shareholders: The grant of options to a director aligns their interests with shareholders, potentially encouraging actions that benefit the company's stock price. However, it also represents potential future dilution if options are exercised.
• Employees: This type of compensation for directors is standard and does not directly impact most employees, though it reflects the company's overall compensation philosophy.
• Management: Heidi Hunter, as a director, receives an incentive tied to company performance.

Next Steps

• The stock options will vest incrementally starting July 5, 2026.
• The options will become fully exercisable by June 5, 2027, or the 2027 annual stockholders meeting.
• Heidi Hunter may choose to exercise these options if the stock price exceeds $26.09.

Key Dates

Keywords

Sutro Biopharma, STRO, Form 4, Stock Options, Insider Trading, Director, Beneficial Ownership, SEC Filing, Equity Award